Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2016) 45 P57 | DOI: 10.1530/endoabs.45.P57

1Paediatric Endocrinology Department, Royal Manchester Children’s Hospital, Manchester, UK; 2Paediatric Surgery Department, Royal Manchester Children’s Hospital, Manchester, UK; 3Faculty of Life Sciences, University of Manchester, Manchester, UK; 4Paediatric Histopathology Department, Royal Manchester Children’s Hospital, Manchester, UK.


Introduction: Congenital Hyperinsulinism (CHI) is a heterogeneous condition caused by dysregulation of insulin secretion. Paternally inherited mutations in ABCC8 or KCNJ11 are associated with loss of the maternal 11p15 allele in focal CHI (CHI-F). CHI-F can be curative after selective lesionectomy. However, histological heterogeneity within the CHI-F lesions has not been previously reported. We aimed to examine the diversity in focal lesions and correlate with clinical phenotypes and outcomes.

Methods: About 20 subjects with CHI-F were included over a 12-year period. About 18F-DOPA PET-CT was used to localise lesions in patients with CHI-F, following mutation testing for ABCC8/KCNJ11. Immunohistochemistry, transmission electron microscopy and serial block face-scanning electron microscopy were used to further characterise the structural organisation within the lesions.

Results: In our group, 85% had paternal heterozygous mutations in ABCC8, and 15% in KCNJ11; one child had a de novo ABCC8 mutation. About 18F-DOPA PET-CT confirmed and localised the focus before surgical lesionectomy. Sixty five percent of patients (13/20) were found to have a clearly demarcated and identifiable mass of insulin-expressing cells in the focal lesion, identified as Type 1 disease. Type 1 CHI-F lesions were encapsulated in a basement membrane that was composed of collagen fibre bundles organized into a loose orthogonal structure. In these patients, lesions were palpable at surgery and a focal lesionectomy was successful and resulted in curative outcomes. By contrast, in 35% of patients islet cell hyperplasia was not tightly encapsulated and not clearly demarcated from healthy tissue, identified as Type 2 disease. Type 2 CHI-F patients presented with symptoms earlier than Type 1 CHI-F (23±20 days vs. 55±17 days), the surgical procedure was more complex and not completely curative in 50% of the patients. It was not possible to distinguish Type 2 CHI-F from Type 1 by 18F-DOPA uptake profiles, and there were no correlation between the subtypes of CHI-F and the genetic basis of disease.

Conclusions: CHI-F has an underlying heterogeneity in the organisation of focal lesions, unrelated to the genotype and not identifiable with 18F-DOPA-PET-CT. Classification into Types 1 and 2 has implications for surgical margin of resection and predicting disease outcomes.

Volume 45

44th Meeting of the British Society for Paediatric Endocrinology and Diabetes

British Society for Paediatric Endocrinology and Diabetes 

Browse other volumes

Article tools

My recent searches

No recent searches.